ZIMP
BMRN icon

Zimmermann Investment Management & Planning’s BioMarin Pharmaceuticals BMRN Stock Holding History

Zimmermann Investment Management & Planning’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,363
Closed -$562K – 84
2021
Q4 		$562K Buy
+6,363
New +$525K 0.32% 55

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Zimmermann Investment Management & Planning's BMRN Position: Q1 2022 in Review

Zimmermann Investment Management & Planning sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 6,363 shares — an estimated $562K sold.

Zimmermann Investment Management & Planning first reported a position in BMRN in Q4 2021 and held it in 1 quarter. The position peaked at $562K in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Zimmermann Investment Management & Planning reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Zimmermann Investment Management & Planning sold 6,363 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $562K.
  • Zimmermann Investment Management & Planning first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Zimmermann Investment Management & Planning's BioMarin Pharmaceuticals position peaked at $562K in Q4 2021.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Zimmermann Investment Management & Planning's 13F filing for Q1 2022, filed 18 Apr 2022.